CDC Logo Tuberculosis Information CD-ROM   Image of people
     
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

 

U.S. Department of Health and Human Services

  

Education Materials > Publications > Self-Study Modules on TB > Module 4 > Study Questions

Self-Study Modules on Tuberculosis

This is an archived document. The links are no longer being updated.

Module 4: Treatment of Tuberculosis Infection and Disease

Answers To Study Questions

4.1. What is the purpose of preventive therapy?

The purpose of preventive therapy is to prevent people with TB infection from developing TB disease.

4.2. Which groups of people should receive high priority for preventive therapy if they have a positive skin test reaction, regardless of their age? Name six.

  • People with HIV infection
  • Close contacts of people with infectious TB disease
  • People whose skin test reaction converted from negative to positive within the past 2 years
  • People with chest x-ray findings suggestive of previous TB disease
  • People who inject illicit drugs
  • People with medical conditions that appear to increase the risk for TB disease

4.3. Which groups of people should receive high priority for preventive therapy if they have a positive skin test reaction and are younger than 35? Name five.

  • People born in areas of the world where TB is common (for example, Asia, Africa, or Latin America)
  • Low-income groups with poor access to health care
  • People who live in residential facilities (for example, nursing homes or correctional facilities)
  • Children younger than 4 years old
  • People in other groups as identified by local public health officials

4.4. In what circumstances may preventive therapy be given to people who have a negative tuberculin skin test reaction?

Some close contacts may start taking preventive therapy if they have a negative skin test reaction but less than 10 weeks have passed since they were last exposed to TB. These contacts include
  • High-risk contacts who have a negative skin test reaction (including contacts who are anergic). High-risk contacts are young children, adolescents, HIV-infected people, and others who may develop TB very quickly after infection.
  • Close contacts who have a negative skin test reaction, if many other close contacts have a positive skin test reaction
These contacts should be retested 10 weeks after they were last exposed to TB. If they have a negative skin test reaction, they can stop taking preventive therapy. (HIV-infected contacts may be given a full course of preventive therapy, regardless of their skin test results.) If they have a positive skin test reaction, they should continue to take preventive therapy.

Also, children younger than 6 months old who have been exposed to TB should start taking preventive therapy, even if they have a negative skin test reaction. The children should be retested when they are 6 months old. If they have a negative skin test reaction and 10 weeks have passed since they were last exposed to TB, the preventive therapy may be stopped.

4.5. Name three reasons why patients should receive a medical evaluation before starting preventive therapy.

All patients being considered for preventive therapy should receive a medical evaluation to
  • Exclude the possibility of TB disease
  • Determine whether they have ever been treated for TB infection or disease
  • Identify any medical problems that may complicate therapy or require more careful monitoring

4.6. Why is it important to exclude the possibility of TB disease before giving a patient preventive therapy?

It is important to exclude the possibility of TB disease because treating TB disease with a preventive therapy regimen (usually a single drug) can lead to drug resistance.

4.7. What is the usual preventive therapy regimen? How is it different for children and HIV-infected people?

The usual regimen for preventive therapy is isoniazid given daily for 6 months. Children should receive at least 9 months of preventive therapy; HIV-infected persons should receive 12 months of preventive therapy.

4.8. What preventive therapy regimen is recommended for people with a positive skin test reaction who have been exposed to isoniazid-resistant TB?

Preventive therapy with rifampin is recommended in this situation.

4.9. What adverse reactions may be caused by isoniazid? Name two, and define each.

Isoniazid may cause hepatitis or peripheral neuropathy. Hepatitis is damage to the liver. Peripheral neuropathy is damage to the sensory nerves of the hands and feet.

4.10. What are the symptoms of hepatitis?

The common symptoms of hepatitis are nausea, vomiting, abdominal pain, fatigue, and dark urine.

4.11. How often should patients be evaluated for signs and symptoms of adverse reactions during preventive therapy?

All persons receiving preventive therapy should be evaluated at least monthly during therapy for signs and symptoms of adverse reactions. During each monthly evaluation, clinicians should ask patients whether they have nausea, abdominal pain, or any of the other symptoms that may be caused by adverse reactions. In addition, they should examine patients for signs of these adverse reactions.

4.12. Who is at greatest risk for hepatitis? What special precautions should be taken for these patients?

The people at greatest risk for hepatitis are
  • People 35 years of age and older
  • People with a history of liver disease
  • People who abuse alcohol
  • People who inject illicit drugs
  • People who are taking other medications that may increase the risk of hepatitis

These patients should have liver function tests before starting isoniazid preventive therapy and every month during therapy. In addition, more careful monitoring -- and possibly more liver function tests -- should be considered for black and Hispanic women because they may be at increased risk for isoniazid-associated hepatitis.

4.13. Why must TB disease be treated for at least 6 months?

TB disease must be treated for at least 6 months in order to kill all of the tubercle bacilli. Most of the bacilli are killed during the first 8 weeks of treatment (initial phase). However, a few bacilli become dormant (inactive), and they can remain dormant for a long time. The drugs used to treat TB do not work as well against dormant bacilli as they do against bacilli that are growing (active). Therefore, treatment must be continued for several more months to kill these few remaining bacilli (continuation phase). If treatment is not continued for a long enough time, some bacilli may survive and cause TB disease at a later time (relapse).

4.14. Which four drugs are recommended for the initial treatment of TB disease?

In most areas of the country, the initial regimen for treating TB disease should include isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and either ethambutol (EMB) or streptomycin (SM). When the drug susceptibility results are available, clinicians may change the regimen accordingly. In areas where less than 4% of cases are resistant to INH (first drug susceptibility test only), three drugs (INH, RIF, and PZA) may be adequate for the initial regimen.

4.15. Why should at least two drugs be used to treat TB disease?

Using only one drug to treat TB disease can create a population of tubercle bacilli that is resistant to that drug. When two or more drugs are used together, each drug helps prevent the emergence of bacilli that are resistant to the other drugs.

4.16. Name two factors that can lead to drug resistance.

Drug resistance can develop when patients are prescribed an inappropriate regimen for treatment or when patients do not follow treatment regimens as prescribed.

4.17. What is directly observed therapy? Why should it be considered for all patients?

Directly observed therapy means that a health care worker or another designated person watches the patient swallow each dose of the prescribed drugs. This method of treatment should be considered for all patients because there is no way to predict reliably which patients will adhere to treatment.

4.18. In what special situations should treatment for TB disease last longer than the usual course of treatment?

Infants and children with miliary TB, bone and joint TB, or TB meningitis should receive at least 12 months of treatment.

Pregnant women with TB should receive at least 9 months of treatment.

Treatment for isoniazid-resistant TB can last 12 months when a regimen of rifampin and ethambutol is used, and treatment for multidrug-resistant TB can last 2 years or longer.

4.19. Name the drug or drugs that may cause each of the following symptoms or adverse reactions.

Ear damage: streptomycin

Hepatitis: isoniazid, pyrazinamide, rifampin

Eye damage: ethambutol

Orange discoloration of the urine: rifampin

4.20. How often should patients be monitored for adverse reactions to TB drugs?

All patients should be seen by a clinician at least monthly during treatment and evaluated for possible adverse reactions. During this evaluation, clinicians should ask patients whether they have any of the symptoms that may be due to adverse reactions and examine patients for signs of possible adverse reactions. Also, public health workers who have regular contact with patients should ask patients about adverse reactions at every visit.

4.21. Name four ways that clinicians can assess whether a patient is adhering to treatment.

Check to see whether the patient is reporting to the clinic as scheduled

Ask the patient to bring the prescribed medications to each clinic visit and count the number of pills to determine how many have been taken

Use special urine tests to detect the presence of the prescribed medication in the urine

Assess the patient's clinical response to therapy

4.22. What is the best way to ensure that a patient adheres to treatment?

The best way to ensure adherence to therapy is to use directly observed therapy.

4.23. How can clinicians determine whether a patient is responding to treatment?

To determine whether a patient is responding to therapy, clinicians should do clinical evaluations and bacteriologic evaluations during therapy. Clinicians may also use x-rays to monitor a patient's response to treatment, especially in patients who have negative culture results before treatment or who have certain types of extrapulmonary TB.

4.24. Under what circumstances should patients be reevaluated?

Patients should be reevaluated promptly if their

  • Symptoms do not improve during the first 2 months of therapy
  • Symptoms worsen after improving initially
  • Culture results have not become negative after 2 months of treatment
  • Culture results become positive after being negative

4.25. What does reevaluating the patient mean?

Reevaluating the patient means checking for drug resistance by repeating the drug susceptibility tests and assessing whether the patient has been taking medication as prescribed.

4.26. What should a public health worker do if he or she notices that a patient has symptoms of an adverse reaction?

The public health worker should

  • Instruct the patient to stop the medication if the symptoms are serious (before working with TB patients, public health workers should be educated about which symptoms are serious)
  • Report the situation to a clinician and arrange for a medical evaluation right away
  • Note the symptoms on the patient's form

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333